GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: ARIA
Underweight $6

Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) reiterated to Underweight with price target $6 by Barclays

Tuesday,  Jan 19, 2016  1:25 PM ET by Lynn Gilbert

Barclays reiterated Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) to Underweight with price target
$6. Previously, Barclays rated Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) to Underweight with price target $4 on 10/10/2013, when the stock price was valued at $5.42.

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

Barclays



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy